

Supplementary Table S3 Number of deaths from any cause up to end of study in the placebo and selexipag arms (intent-to-treat analysis) among patients with PAH-CTD

	Placebo (N=167)	Selexipag (N=167)
Cumulative all-cause deaths n		
Month 6 (Week 26)	8	9
Month 12	18	16
Month 18	23	22
Month 24	29	28
End of study	34	33

CTD: connective tissue disease; PAH: pulmonary arterial hypertension